References
- World Health Organization. Composite international diagnostic interview (CIDI) core version 2. World Health Organization, Geneva O. 1996
- Adlaf E M, Lvis F G, Smart R G. Alcohol and other drug use among Ontario adults in 1994 and changes since 1977. Addiction Research Foundation, Toronto 1994
- Derogatis L R. The symptom checklist 90–R: administration, scoring and procedures manual. 3rd ed. National Computer Systems, Minneapolis 1994
- Brower K J, Eliopulos G A, Blow G C, Catlin D H, Beresford T P. Evidence for physical and psychological dependence on anabolic-androgenic steroids in eight weight lifters. American Journal of Psychiatry 1990; 147: 510–512
- Brower K J, Blow F C, Young J P, Hill E M. Symptoms and correlates of anabolic-androgenic steroid dependence. British Journal of Addiction 1991; 86: 759–768
- Sawyer M G, Meldrum D, Tonge B, Clark J. Mental health and young people. A report into the nature of mental health problems experienced by young people and implications for service provision. National Clearing House for Youth Studies, Hobart 1992
- Patton G. An epidemiological case for a separate adolescent psychiatry. Australian and New Zealand Journal of Psychiatry 1996; 30: 563–566
- Varma S, Zain L. AM. Religion and spirituality. Australian and New Zealand Journal of Psychiatry 1997; 31: 604–606
- Sher L. The placebo effect on mood and behaviour: the role of the endogenous opioid system. Medical Hypothese 1997; 48: 347–349
- Jevning R, Wilson A F, Vander-Laan E F. Plasma prolactin and growth hormone during meditation. Psychosomatic. Medicine 1978; 40: 329–333
- Massion A, Teas O. J., Hebert J R, Wertheimer M D, Kabat-Zinn J. Meditation, melatonin and breast/prostate cancer: hypothesis and preliminary data. Medical Hypotheses 1995; 44: 39–46
- MacLean C RK, Walton K G, Wenneberg S R, et al. Effects of the Transcendental Meditation program on adaptive mecha nisms: changes in hormone levels and responses to stress after 4 months of practice. Psychoneuroendocrinology 1997; 22: 1277–295
- Kaplan H I, Sadock B J, Grebb J A. Kaplan and Sadock's synopsis of psychiatry: behavioural sciences, clinical psychia try, 7th ed. Williams and Wilkins, Baltimore, MD 1994
- Elias A N, Wilson A F. Serum hormonal concentrations fol lowing transcendental meditation—potential role of gamma-aminobutyric acid. Mrdical Hypotheses 1995; 44: 287–291
- Essali M A, Rezk E, Wahlheck K, Cheine M. Clozapine vs ‘typical’ neuroleptic medication for schizophrenia. The Cochrane Database of Systematic Reviews. 1997, [updated 04 March
- Medelowicz A, Stanton G L, Alvir J, Lieherman J. Closapine-induced agranulocytosis: risk factors, monitoring and management. CNS Drugs 1995; 4/6: 412–421
- April 29, 1997; 10, Zyprexa product monograph
- March 14, 1997, Risperdal product monograph
- Shoshani D, Dorman P, Lokshin P, et al. Clozapine-induced agranulocytosis: can olanmpine be a safer alternative?. European Neuropharmacology 1997; 7(Suppl.2)221
- Flynn S W, Altman S, Macewan G W, Black L L, Greenidge L L, Honer W G. Prolongation of clozapine-induced granulo-cytopaenia associated with olanzapine. Journal of Clinical Psyhopharmacology 1917; 17: 494–495
- Ellard J. Tests in psychiatry. Australian and New Zealand Journal of Psychiatry 1997; 31: 808–811